Character is a precision medicine company focused on macular degeneration and primary open-angle glaucoma, utilizing clinical genomic databases and machine learning to identify genetic drivers of disease progression. By characterizing patient subtypes, Character aims to develop targeted therapies for conditions that currently have limited treatment options.
Funding
$24M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) are progressive polygenic diseases that are currently treated as homogeneous conditions, despite diverse patient subtypes and disease progression patterns. This lack of granularity limits the effectiveness of existing treatments.
Solution
Character is a precision medicine company focused on identifying the genetic drivers of disease progression in AMD and POAG. The company builds clinical genomic databases and applies machine learning to characterize patient subtypes, enabling the discovery and development of targeted therapies. By integrating genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes, Character aims to increase the probability of success for translating discoveries into medicines. The company's platform facilitates drug target selection, clinical endpoint prioritization, patient stratification, and accelerated clinical trial execution.
Target Audience
The primary target audience includes patients, ophthalmologists, treating physicians, and industry partners interested in advancing precision medicine for ophthalmic diseases like AMD and POAG.
Features
- World-class clinical genomic databases in AMD and POAG to characterize the diversity of patient subtypes.
- Integration of genomics with longitudinal clinical data, ophthalmic imaging, and AI/ML-powered quantification of disease progression phenotypes.
- Identification of drug targets and pathways associated with disease progression.
- Development and evaluation of multimodal patient biomarkers for patient stratification.
- AI/ML powered quantification of disease progression phenotypes and clinical endpoints.